Buena entrada, pillado el dip, de -10% a verde A parte del variado portfolio, es interesante la fabricación de saponinas necesarias para fabricar las vacunas COVID AGEN
#127175
Re: Farmas USA
Os acompaño a 5,13 un poquito mas caras pero seguro que no comprasteis para vender en mi precio jeje, suerte !! Agen
TG Therapeutics (NASDAQ:TGTX) has surged ~6.1% after the FDA announced the approval for Ukoniq (umbralisib) for the treatment of adults with relapsed or refractory marginal zone lymphoma who have received at least one prior anti-CD20 based regimen.
The approval is also granted for Ukoniq in the treatment of adult patients with relapsed or refractory follicular lymphoma who have undergone at least three prior lines of systemic therapy.
In August, TG Therapeutics announced that the regulator accepted the marketing application for the therapy in MZL under the priority review status setting an FDA action date of February 15, 2021. With a standard review, the FL indication had a PDUFA goal date of June 15, 2021
The new drug application was supported by umbralisib monotherapy MZL and FL cohorts in a Phase 2b trial evaluating patients with relapsed/refractory MZL or FL.
